CRISPR-Cas9 gene correction is a therapeutic tool which may abolish half of the known genetic disorders. To achieve this we need to deliver three macromolecules into the nucleus simultaneously, as well as trigger the homology-directed repair (HDR) pathway. The focus of this poster is on the role of mitosis on the state of these barriers, which in theory removes the nuclear membrane barrier and primes the cell for the HDR pathway.
The mitotic state of the cell skews the gene-editing outcome greatly, indicating a need to target mitotic cells for therapeutic gene correction.
You have attended this session. This session has ended. Click here to join another session or go to My Sessions.
Guests attending this workshop
Request Login
Registration
Profile
Danny Wilbie
Country
Company
Utrecht University
Job title
PhD Candidate
Interests
Protein delivery, CRISPR, gene therapy
About me
I am a second year PhD candidate in the Department of Pharmaceutics at UU university, in the group of Enrico Mastrobattista. My research focusses on the feasibility of applying CRISPR/Cas gene editing for gene correction in vivo.
Justine Toulotte
Country
Company
UU, Faculty of Science
Job title
PhD student
Interests
About me
Julia Egido
Country
Company
UMC Utrecht
Job title
PhD candidate
Interests
About me
Ingrid Jordens
Country
Company
UMC Utrecht
Job title
Postdoc
Interests
About me
Patrique Praest
Country
Company
UMCU
Job title
Postdoc
Interests
About me
Laura Hofman
Country
Company
Princess Maxima Center for Pediatric Oncology
Job title
Master student
Interests
About me
Mert Öktem
Country
Company
UU, Faculty of Science
Job title
PhD student
Interests
About me
Boning Qiu
Country
Company
UU, Faculty of Science
Job title
PhD student
Interests
About me
Zhiyong Lei
Country
Company
UMC Utrecht
Job title
Assistant Professor
Interests
About me
Connection Request
How it works
Complete your profile
Take a seat
Meet the others and have fun!
Share
Be nice and share your participation on social media!